Affimed N.V.

Affimed N.V.: Proprietary ROCK® platform enabling generation of multi-specific antibodies is basis for its collaboration with Genentech ($96M upfront / $5B potential) to develop NK-cell engager-based therapeutics. Pipeline includes NK cell engager AFM13 (CD30/CD16A) to enter Ph 2 registration study in CD30-positive PTCL and an investigator-sponsored study by MDACC of AFM13 combined with allogeneic NK cells in relapsed/refractory CD30-positive lymphoma. IND cleared for AFM24, the company’s innate cell engager that targets EGFR-expressing solid tumors.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, USA
Clinical Stage
Phase l or ll
Disease Space
Hematology, Immuno-Oncology, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
Im Neuenheimer Feld 582
Heidelberg, Baden-Wurttemberg 69120
Germany

Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13

  • Adi Hoess, Ph.D., Chief Executive Officer
  • Gregory Gin, Head of Investor Relations

Lead Programs

AFM13

Disease Target CD30 Immune Cell Target CD16A

Indication Phase
Hodgkin lymphoma + PD-1 1
Hodgkin lymphoma 2
Hodgkin lymphoma + adoptive NK cells Pre-clinical
CD30-positive lymphoma 2

AFM24

Disease Target EGFRwt Immune Cell Target CD16A

Indication Phase
Solid tumors Pre-clinical

Top 10 Holders of Affimed N.V.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
NEA Management Co. 8.04 6,126,488 37.86 13F 9/30/20
Millennium Management LLC 5.57 4,246,451 26.24 13F 9/30/20
683 Capital Management LLC 4.79 3,650,000 22.56 13F 9/30/20
BlackRock Fund Advisors 4.41 3,360,265 20.77 13F 9/30/20
Citadel LP 4.16 3,173,215 19.61 13F 9/30/20
Bain Capital Public Equity Management II LLC 2.82 2,148,513 13.28 13F 9/30/20
Point72 Asset Management LP (Old) 2.62 2,000,000 12.36 13F 9/30/20
Acadian Asset Management LLC 2.49 1,900,379 11.74 13F 9/30/20
State Street Corp. 2.08 1,589,594 9.82 13F 9/30/20
Eversept Partners LP 1.63 1,245,458 7.70 13F 9/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.